Effect of Mexidol on the quality of life and functional status of patients with chronic cerebral ischemia and chronic heart failure with reduced left ventricular ejection fraction

2021 ◽  
Vol 14 (1) ◽  
pp. 80
Author(s):  
V.V. Tolkacheva ◽  
E.R. Kazakhmedov ◽  
Zh.D. Kobalava ◽  
S.A. Galochkin ◽  
A.V. Shchulkin
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Cerebral Ischemia ◽  
Chronic Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Chronic Cerebral Ischemia ◽  
Ventricular Ejection Fraction

scholarly journals Interim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure

Kardiologiia ◽  
2021 ◽  
Vol 61 (7) ◽  
pp. 22-27
Author(s):  
S. N. Tereschenko ◽  
N. B. Perepech ◽  
I. A. Cheremisina ◽  
V. N. Belov ◽  
Y. A. Vollis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Ventricular Ejection ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Aim      Improvement of quality of life is one of the most important goals for the treatment of patients with chronic heart failure (CHF). This study searched for ways to increase the efficiency of CHF treatment based on parameters of quality of life in CHF patients during and after the treatment with exogenous phosphocreatine (EP).Material and methods  The effect of a single course of EP treatment on quality of life of patients with functional class (FC) II-IV CHF with reduced or mid-range left ventricular ejection fraction was studied as a part of the all-Russia prospective observational study BYHEART. The presence of FC II-IV CHF and a left ventricular ejection fraction <50 % were confirmed by results of 6-min walk test (6MWT) and findings of echocardiography after stabilization of the background therapy.Results An interim data analysis showed that the course of EP treatment was associated with a significant improvement of quality-of-life indexes as determined by the Minnesota Living with Heart Failure Questionnaire (LHFQ) total score. These indexes significantly increased and remained at a satisfactory level for 6 mos. following completion of the treatment course. Also, the treatment significantly beneficially influenced the clinical condition of patients (heart failure severity scale), results of 6MWT, and the increase in left ventricular ejection fraction.Conclusion      The conclusions based on results of the interim analysis should be confirmed by results of the completed study. Complete results are planned to be published in 2022.

scholarly journals Pentoxyphylline: possibilities to reduce manifestations of chronic heart failure with preserved left ventricular ejection fraction in elderly

2021 ◽  
Vol 23 (1) ◽  
pp. 24-31
Author(s):  
V. B. Shatylo ◽  
L. A. Bodretska ◽  
I. S. Shapovalenko ◽  
H. P. Voinarovska ◽  
Zh. S. Butynets
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Ventricular Ejection ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

The aim: to study the effect of add-on pentoxifylline therapy on the structural and functional indicators of the heart state, endothelial function, quality of life and physical abilities in patients with chronic heart failure with preserved left ventricular ejection fraction. Materials and methods. The indicators of the structural and functional state of the heart, endothelial function, quality of life and physical abilities of patients older than 60 years, who were followed-up in the Department of Cardiology of the State Institution “D. F. Chebotarev Institute of Gerontology of the NAMS of Ukraine”, based on 67 case histories, 37 of them were prescribed pentoxifylline as add-on therapy to the standard therapeutic regimen. Statistical data were calculated using modern application packages, in particular SPSS v.22, Statistica 7.0, MedCalc statical software v.11.5.0.0. The significance level was assessed using paired and unpaired Student's t-test with Bonferroni corrections, and the correlation and two-way analysis of variance were performed. Results. A significant additional effect of pentoxifylline treatment on the indicators of maximum blood flow in the forearm microvessels in response to the reactive hyperemia test, which characterizes the ability of the microvessel endothelium to synthesize relaxation factors, was detected. Patients who additionally received pentoxifylline showed significantly better indicators of left ventricular myocardial relaxation and reduction of hypertrophy than those on the standard therapy. There was a significant increase in walking distance in the third year of treatment in the patients who additionally received pentoxifylline. There was no difference in the impact on the quality of life of the patients. Conclusions. The addition of pentoxifylline to the standard therapy in patients with chronic heart failure with preserved left ventricular ejection fraction significantly reduces myocardial hypertrophy, improves diastolic relaxation, increases volumetric blood flow velocity in microvessels mediating reactive hyperemia, which may contribute to further stabilizing the clinical course of the disease and increasing 6-minute walking distance. The presented data are an additional evidence of pathogenetically reasonable therapy with pentoxifylline in patients with chronic heart failure with preserved left ventricular ejection fraction, which allows us to consider this drug as potentially promising for the routine treatment of such patients.

scholarly journals Comparative analysis of clinical and neurological manifestations in patients with chronic cerebral ischemia and chronic heart failure with stored and reduced release fraction

2017 ◽  
pp. 43-52
Author(s):  
N. Zhhilova
Keyword(s):  
Heart Failure ◽  
Nervous System ◽  
Comparative Analysis ◽  
Cerebral Ischemia ◽  
Chronic Heart Failure ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Neurological Manifestations ◽  
Chronic Cerebral Ischemia ◽  
Ventricular Ejection Fraction

The activation of the sympathetic nervous system plays an important pathophysiological role in the development of heart failure, in particular, in the development of left ventricular insufficiency. Although high blood pressure is considered as the main determinant of structural changes in the left ventricle, sex, salt intake, obesity, diabetes, as well as neurohumoral and genetic factors can affect the mass and left ventricular geometry. The usual concept of hypertonic re-modeling. In the comparative analysis of clinical and neurological manifestations in patients with chronic cerebral ischemia and chronic heart failure with a preserved and reduced release fraction, changes in the nervous system that showed a tendency to increase the disturbances and deviations from the norm with increasing heart failure, the fraction of release and the presence of hypertensive encephalopathy In the correlation analysis, a direct correlation between the quality of life indicator and the degree of heart failure (r = 0.56), the presence of myocardial infarction in the history (r = 0.42), arterial hypertension (r = 0.33) and the presence of valvular pathology the heart (r = 0.31) and the inverse correlation dependence on the indicator of the left ventricular ejection fraction (r = -0.69). A comparative analysis of correlation relationships indicates a reliable clinical and social significance of the left ventricular ejection fraction in patients with chronic cerebral ischemia and chronic heart failure.

scholarly journals Correlation between Suppression of Tumorigenicity-2 with Left Ventricular Geometry, Left Ventricular Ejection Fraction and Quality of Life in Systolic Heart Failure Patients

2020 ◽  
Vol 12 (3) ◽  
pp. 233-8
Author(s):  
Johan Gunadi ◽  
Starry Homenta Rampengan ◽  
Janry Antonius Pangemanan ◽  
Agnes Lucia Panda ◽  
Nancy Lampus ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Systolic Heart Failure ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Left Ventricular Geometry ◽  
Ventricular Ejection Fraction ◽  
Ventricular Geometry

BACKGROUND: Heart failure (HF) is a clinical syndrome caused by structural or functional cardiac disorders and is the final stage of every heart disease, marked by decreased functional capacity and patients’ quality of life (QoL). Suppression of tumorigenicity-2 (ST2) is a biomarker depicting heart fibrosis and remodeling that altered left ventricular geometry, which in turn decreases left ventricular contractility, decreases functional capacity, and ultimately affects the QoL of the HF patient.METHODS: An observational study was conducted with a cross-sectional approach involving 60 patients with systolic heart failure. Left ventricular geometry, left ventricular ejection fraction (LVEF), ST2 level, and other biomarkers were examined, continued by QoL assessment.RESULTS: The ST2 level (33.25±23.55 ng/mL) was negatively correlated with LVEF (r=-0.257; p=0.024) and was positively correlated with QoL (r=0.255; p=0.05). The LVEF was negatively correlated with QoL (r=-0.224; p=0.031). However, no significant correlation was found between left ventricular geometry with ST2 level or patients’ QoL.CONCLUSION: Elevated ST2 levels are correlated with decreased LVEF and worse QoL in systolic heart failure subjects. Therefore, ST2 together with LVEF can be used as prognostic tools for patients with HF.KEYWORDS: heart failure, ST2, left ventricular geometry, left ventricular ejection fraction, quality of life

scholarly journals Thiamin supplementation does not improve left ventricular ejection fraction in ambulatory heart failure patients: a randomized controlled trial

2019 ◽  
Vol 110 (6) ◽  
pp. 1287-1295 ◽  
Author(s):  
Mary Keith ◽  
Shirley Quach ◽  
Mavra Ahmed ◽  
Parastoo Azizi-Namini ◽  
Abdul Al-Hesayen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Placebo Group ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Ambulatory Patients

ABSTRACT Background Thiamin, a water-soluble B-complex vitamin, functions as a coenzyme in macronutrient oxidation and in the production of cellular ATP. Data suggest that thiamin depletion occurs in heart failure (HF). Therefore, thiamin supplementation in HF patients may improve cardiac function. Objective We sought to determine whether oral thiamin supplementation improves left ventricular ejection fraction (LVEF), exercise tolerance, and quality of life among patients with HF and reduced LVEF. Methods In this prospective, multicenter, double-blind, placebo-controlled randomized trial, eligible ambulatory patients with HF and reduced LVEF were recruited from 4 academic and community hospitals between 2010 and 2015. Participants were randomly assigned to receive either 200 mg oral thiamin mononitrate per day or placebo for 6 mo. Results Sixty-nine patients (mean ± SD age: 64 ± 12 y; 83% men; LVEF: 37% ± 11%) were randomly assigned: 34 received placebo and 35 received thiamin supplementation. Erythrocyte thiamin pyrophosphate and urine thiamin concentrations were significantly higher in the supplemented group than in the placebo group at 6 mo (P = 0.02 and <0.001, respectively). At 6 mo, LVEF was significantly higher in the placebo group than in the thiamin group (38%; 95% CI: 36%, 39% compared with 35%; 95% CI: 33%, 37%, P = 0.047) after adjusting for baseline measurements. There were no significant differences in Minnesota Living with Heart Failure score, distance walked in 6 min, and N-terminal prohormone of brain natriuretic peptide concentrations between the 2 groups. One patient (2.9%) in the thiamin-supplemented group and none in the control group died at 6 mo. Conclusions In ambulatory patients with HF and reduced LVEF, thiamin supplementation for 6 mo did not improve LVEF, quality of life, or exercise capacity, despite increases in thiamin concentrations. These findings do not support routine thiamin supplementation in the treatment of HF and reduced LVEF. This trial was registered at clinicaltrials.gov as NCT00959075.

scholarly journals Comparison of effectiveness of therapy with lisinopril and fosinopril in patients with diastolic chronic heart failure in the presence of hypertension disease

2019 ◽  
Vol 16 (2) ◽  
pp. 6-11
Author(s):  
Svetlana N Merzlyakova ◽  
Iosif Z Shubitidze ◽  
Vitalii G Tregubov ◽  
Vladimir M Pokrovskiy
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Combination Therapy ◽  
Systolic Function ◽  
Subjective Evaluation ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Aim. Сompare the effectiveness of combination therapy with lisinopril and fosinopril in patients with diastolic chronic heart failure (CHF) in the presence of hypertension disease (HD), considering its impact on the regulatory adaptive status (RAS). Materials and methods. The study take parted 69 patients with CHF II functional class according to the classification of the New York Heart Association in the presence of HD III stage with preserved systolic function of the left ventricle (left ventricular ejection fraction ≥50%), who were randomized into two groups for treatment with lisinopril (13.7±3.7 mg/day, n=34) or fosinopril (14.5±4.1 mg/day, n=35). As part of combination pharmacotherapy, patients were included nebivolol (7.2±2.4 mg/day and 7.0±2.2 mg/day), and acetylsalicylic acid when required (100 mg/day, n=8 and 100 mg/day, n=7), atorvastatin (15.7±4.9 mg/day, n=14 and 16.9±4.6 mg/day, n=16) respectively. Initially and after six months, the following was done: a quantitative evaluation of the RAS (by cardio-respiratory synchronism test), echocardiography, holter monitoring of blood electrocardiograms, all-day monitoring of pressure, treadmill test, determination of the N-terminal precursor of the natriuretic brain peptide level in blood plasma, six-minute walking test, subjective evaluation of quality of life. Results. Both combined pharmacotherapy schemes comparably improved structural and functional state of the heart, neurohumoral activation and optimized blood pressure. However, in this case, the use of fosinopril, in comparison with lisinopril, positively affected on RAS, increased exercise tolerance and improved quality of life more. Conclusion. In patients with diastolic CHF in the presence of HD III stage as part of the combination therapy, the use of fosinopril, in comparison with lisinopril, may be preferable because of a more pronounced positive effect on RAS.

scholarly journals Assessment of the effect of nebivolol and сarvedilol on the functional state of patients with diastolic chronic heart failure

2021 ◽  
Vol 11 (4) ◽  
pp. 25-29
Author(s):  
Vitalii G. Tregubov ◽  
Pavel V. Khil′kevich ◽  
Iosif Z. Shubitidze ◽  
Anna V. Tregubova
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Combination Therapy ◽  
Functional State ◽  
Combined Therapy ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Aim. To determine the effect of combined therapy with nebivolol or carvedilol on the functional state of patients with diastolic chronic heart failure (CHF). Material and methods. The study involved 68 patients with CHF and preserved left ventricular ejection fraction, who were randomized into two groups for treatment with bisoprolol or carvedilol. As part of the combination therapy was prescribed quinapril, and if indicated atorvastatin, acetylsalicylic acid in the intestinal soluble shell. Initially and after 24 weeks of therapy were carried out: quantitative assessment of regulatory-adaptive status (RAS), echocardioscopy, treadmill test, six-minute walking test, subjective assessment of quality of life, determination of level of N-terminal fragment of the brain natriuretic peptide precursor in blood plasma. Results. Both schemes of combined therapy comparably improved the morpho-functional parameters of the heart and quality of life. In comparison with carvedilol, nebivolol more pronouncedly increased RAS and tolerance to physical activity. Conclusion. In patients with diastolic CHF in combination therapy, the use of nebivolol, in comparison with carvedilol, may be preferable due to the positive effect on the functional state.

scholarly journals CPAP in chronic heart failure

2013 ◽  
pp. 47-51
Author(s):  
F. Lari ◽  
G.P. Bragagni ◽  
G. Pilati ◽  
N. Di Battista
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Sleep Disorders ◽  
Ventricular Volume ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Negative Effects ◽  
Ventricular Ejection Fraction

BACKGROUND Chronic Heart Failure (CHF) represents worldwide a clinical condition with increasing prevalence, high social, economical and epidemiological impact. Even if new pharmacological and non-pharmacological approachs have been recently used, mortality remains high in general population and quality of life is poor in these patients. DISCUSSION The association between CHF and sleep disorders is frequent but still undervalued: sleep apnoeas in CHF produce negative effects on cardiovascular system and an aggravation of prognosis. CPAP (Continuous Positive Airway Pressure) is commonly used to treat sleep apnoeas in patients without cardiac involvement and it is also used in first line treatment of acute cardiogenic pulmonary oedema thanks to its hemodynamic and ventilatory effects. The addition of nightly CPAP to standard aggressive medical therapy in patients with CHF and sleep apnoeas reduces the number of apnoeas, reduces the blood pressure, and the respiratory and cardiac rate, reduces the activation of sympathetic nervous system, the left ventricular volume and the hospitalization rate; besides CPAP increases the left ventricular ejection fraction, amd the oxygenation, it improves quality of life, tolerance to exercise and seems to reduce mortality in patients with a higher apnoeas suppression. CONCLUSIONS These implications suggest to investigate sleep apnoeas in patients with CHF in order to consider a possible treatment with CPAP. Further studies need to be developed to confirm the use of CPAP in patients with CHF without sleep disorders.

Sign in / Sign up

Export Citation Format

Share Document